Dizocilpine enhances striatal tyrosine hydroxylase and aromatic L-amino acid decarboxylase activity

https://doi.org/10.1016/0922-4106(95)90173-6Get rights and content

Abstract

Dizocilpine administration enhances dopamine metabolism in the rat striatum, nucleus accumbens, olfactory tubercle, and prefrontal cortex. Concomitant with increased metabolism is enhanced tyrosine hydroxylase and aromatic L-amino acid decarboxylase activities in the striatum and increased mRNA for the two enzymes in the midbrain. Activation of dopaminergic neurons may, in part, explain increased locomotor activity in normal animals and the ability of dizocilpine to potentiate the antiparkinsonian action of L-3,4-dihydroxyphenylalanine in an animal model.

References (40)

  • A. Ouagazzal et al.

    Locomotor activation induced by MK-801 in the rat: postsynaptic interactions with dopamine receptors in the ventral striatum

    Eur. J. Pharmacol.

    (1994)
  • A. Pletscher et al.

    The effect of a new decarboxylase inhibitor on endogenous and exogenous monoamines

    Biochem. Pharmacol.

    (1963)
  • J.F. Reinhard et al.

    A rapid and sensitive assay for tyrosine-3-monooxygenase based upon the release of 3H2O and the adsorption of 3[H]-tyrosine by charcoal

    Life Sci.

    (1986)
  • J. Zhang et al.

    Electrophysiological effects of MK-801 on rat nigrostriatal and mesoaccumbal dopaminergic neurons

    Brain Res.

    (1992)
  • M.-Y. Zhu et al.

    Regulation of striatal aromatic L-amino acid decarboxylase: effects of blockade or activation of dopaminergic receptors

    Eur. J. Pharmacol.

    (1993)
  • M. Carlsson et al.

    The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice

    J. Neural Transm.

    (1989)
  • B.V. Clineschmidt et al.

    Central sympathomimetic activity of (+)-5-methyl-10,11-dhydro-5H-dibenzo[a,b]cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties

    Drug. Dev. Res.

    (1982)
  • P.J. Elliott et al.

    Neuroleptic-induced catalepsy as a model of Parkinson's disease II. Effect of glutamate antagonists

    J. Neural Transm.

    (1990)
  • E.D. French et al.

    MK-801, phencyclidine (PCP), and PCP-like drugs increase burst firing in rat A10 dopamine neurons: comparison to competitive NMDA antagonists

    Synapse

    (1993)
  • A. Gjedde et al.

    Striatal L-DOPA decarboxylase activity in Parkinson's disease in vivo: implications for the regulation of dopamine synthesis

    J. Neurochem.

    (1993)
  • Cited by (33)

    • Synthesis and Neurochemistry of Trace Amines

      2016, Trace Amines and Neurological Disorders: Potential Mechanisms and Risk Factors
    • Dopamine D<inf>2</inf>/D<inf>3</inf> receptor binding of [<sup>123</sup>I]epidepride in risperidone-treatment chronic MK-801-induced rat schizophrenia model using nanoSPECT/CT neuroimaging

      2014, Nuclear Medicine and Biology
      Citation Excerpt :

      Chronic administration of NMDA receptor antagonists produced progressive changes on neuronal cell count, cell morphology, locomotor activity, stereotypy, ataxia and cognitive deficits in rats and monkey [34–38]. Importantly, in MK-801animal models, alterations of neuron activity and protein expression in striatal, mesolimbic and mesocortical dopamine systems after drug treatment have been confirmed in previous reports [39–41]. Gandolfi et al., 1993 report that chronic treatment with MK-801 decreases dopamine D2 receptor function in rat striatum [42] and our D2R ELISA result indicates chronic MK-801 treatment significantly levels striatal and midbrain D2R concentration down.

    • Pyrroloquinoline quinone prevents MK-801-induced stereotypical behavior and cognitive deficits in mice

      2014, Behavioural Brain Research
      Citation Excerpt :

      Schizophrenia is a chronic and severe central nervous system disorder affecting approximately 1% of the world population. Previous reports confirm that the noncompetitive NMDA antagonist MK-801 alters neuron activity and protein expression in the dopaminergic system, which has been linked to schizophrenia [41–45]. MK-801 administration has been widely used as to induce schizophrenia-like behaviors in animals such as hyperactivity [46–49], impaired performance in frontal cortex-dependent cognitive tasks [50,51], decreases in social behavior and motivation [52,53], and deficits in sensorimotor gating [54].

    • [ <sup>123</sup>I]Epidepride neuroimaging of dopamine D <inf>2</inf>/D <inf>3</inf> receptor in chronic MK-801-induced rat schizophrenia model

      2012, Nuclear Medicine and Biology
      Citation Excerpt :

      Since MK-801 injection disturbs dopamine system, we evaluate the alteration of tyrosine hydroxylase, the key enzyme in regulation of dopamine synthesis, by anti-tyrosine hydroxylase immunohistochemistry and TH ELISA. Study results show significant increases of TH level, which might indicate huge amount of DA storing in the presynaptic dopamine neurons [23–25,27]. Van Bockstaele et al. reported that a descending glutamatergic pathway projecting from cortical pyramidal neurons to ventral tegmental area (VTA) through γ-aminobutyric acid interneurons inhibits dopamine release from mesolimbic dopamine pathway [28].

    • Opposite effects of glutamate antagonists and antiparkinsonian drugs on the activities of DOPA decarboxylase and 5-HTP decarboxylase in the rat brain

      2000, Brain Research
      Citation Excerpt :

      Hadjiconstantinou et al. [20] demonstrated that dopamine receptor antagonists modestly increased DDC activity in mice, but the use of such drugs in dopamine-deficient parkinsonian patients would exacerbate their condition. On the other hand, we and others have found that various N-methyl-d-aspartate (NMDA) receptor antagonists dramatically stimulated DDC in the nigrostriatal dopamine pathway of rats, suggesting the adjunctive use of these compounds may improve pharmacotherapy with l-DOPA in Parkinson’s disease [7,15,16,19]. l-DOPA is not only decarboxylated by DDC in dopaminergic neurones, but also by 5-HTP decarboxylase (hereafter distinguished as 5-HTPDC) in 5-HTergic neurones [3,39].

    View all citing articles on Scopus

    Tel.: 614-292-7232.

    View full text